With drugs like Novo Nordisk 's Wegovy becoming household names over the last couple of years, it's no surprise that there are quite a few opportunities to invest in the burgeoning market for weight-loss...
A shocking study in The Lancet showed that nearly three-quarters of U.S. adults are overweight or obese. Chances are that by 2050, there will be 260 million overweight Americans. We already have GLP-1...
The future of the weight loss market might not revolve around GLP-1 drugs.
Its GLP-1 medicines are just one reason why it could threaten Novo Nordisk.
Its pipeline is one of the best among weight loss-focused biotechs right now.
Both companies have a clear path to competing successfully in the market.
They're small now, but these stocks could grow much larger.
Could Zealand Pharma be a better option for growth-oriented investors?
The market for anti-obesity drugs is massive one, worth potentially $100 billion or more based on some ...
The risk is higher, but so is the upside when it comes to Zealand Pharma.